Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline.

Moderna will cut around 10% of its global workforce by year-end to reduce costs, as Covid vaccine sales decline. It aims for 8 new product approvals by 2027.

CEO Stephane Bancel announced on Thursday that the company plans to cut nearly 10% of its global workforce by the end of 2025, marking the COVID-19 vaccine maker’s latest restructuring effort. In a ...

[CAMBRIDGE, MASSACHUSETTS] Moderna is cutting about 10 per cent of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline. Read ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Moderna (MRNA) stock in focus as the company plans to cut 10% of its workforce by 2025 amid cost-saving efforts. Read more here.

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual operating expenses by around $1.5 billion by 2027.

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company’s plan to cut costs by $1.5 billion over the next couple ...

Investing.com -- Moderna (NASDAQ: MRNA) is reducing its global workforce by approximately 10%, according to a letter sent to employees by CEO Stephane Bancel.

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid ...